BIG-1: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Sponsor

University Hospital, Angers (Other)

Overall Status

Recruiting

CT.gov ID

NCT02416388

Collaborator

(none)

3,100

Enrollment

Locations

Arms

56.4

Patients Per Site

Study Details

Study Description

Brief Summary

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following allogeneic SCT in first CR, after either myeloablative (MAC) or reduced intensity (RIC) conditioning, will also be evaluated. With an adaptative design, this clinical trial could test up to 3 novel AML agents of interest.

Condition or Disease	Intervention/Treatment	Phase
Acute Myeloid Leukemia (AML)	Drug: Idarubicin Drug: Daunorubicin Drug: HD Cytarabine Drug: Cyclosporine Drug: Methotrexate Drug: Mycophenolic acid (MPA) Drug: vosaroxin Drug: ID cytarabine Drug: Dexamethasone Drug: Venetoclax	Phase 2/Phase 3

Study Design

Study Type:

Interventional

Anticipated Enrollment :

3100 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial

Study Start Date :

Jan 1, 2015

Anticipated Primary Completion Date :

Jun 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: R1-IDA Idarubicin	Drug: Idarubicin Induction chemotherapy : Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min) + cytarabine 200mg/m²/day from D1 to D7 (IV 24 h) Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).
Active Comparator: R1-DAUNO Daunorubicin	Drug: Daunorubicin Induction chemotherapy : Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min) + cytarabine 200mg/m² /day from D1 to D7 (IV 24 h) Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).
Active Comparator: R2-HDAC High dose cytarabine	Drug: HD Cytarabine Consolidation chemotherapy course (s) : -High dose cytarabine: 3g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group
Experimental: R2-IDAC Intermediate dose cytarabine	Drug: ID cytarabine Consolidation chemotherapy course (s) : -Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group
Active Comparator: R3-MAC-MTX Methotrexate and mycophenolic acid	Drug: Methotrexate GvHD prophylaxis post allogeneic SCT : -15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11 Drug: Mycophenolic acid (MPA) GvHD prophylaxis post allogeneic SCT : 720 mg BID from D0 to D+28 for HLA-identical siblings 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors
Experimental: R3-MAC-MPA Cyclosporine and mycophenolic acid	Drug: Cyclosporine GvHD prophylaxis post allogeneic SCT : -Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100 Drug: Mycophenolic acid (MPA) GvHD prophylaxis post allogeneic SCT : 720 mg BID from D0 to D+28 for HLA-identical siblings 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors
Active Comparator: R3-RIC-CICLO Cyclosporine	Drug: Cyclosporine GvHD prophylaxis post allogeneic SCT : -Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100
Experimental: R3-RIC-MPA Cyclosporine and mycophenolic acid	Drug: Cyclosporine GvHD prophylaxis post allogeneic SCT : -Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100 Drug: Mycophenolic acid (MPA) GvHD prophylaxis post allogeneic SCT : 720 mg BID from D0 to D+28 for HLA-identical siblings 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors
Experimental: R4-VOS-IDAC Intermediate dose cytarabine and vosaroxin	Drug: vosaroxin Consolidation chemotherapy course (s) : -70 mg/m² on D1 and D4 Drug: ID cytarabine Consolidation chemotherapy course (s) : -Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group
Active Comparator: R4-IDAC (without VOS) Intermediate dose cytarabine alone	Drug: ID cytarabine Consolidation chemotherapy course (s) : -Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group
Experimental: R4-DEX-HDAC High dose cytarabine and dexamethasone	Drug: HD Cytarabine Consolidation chemotherapy course (s) : -High dose cytarabine: 3g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group Drug: Dexamethasone Consolidation chemotherapy course (s) : -10 mg/12h on D1, D3 and D5
Active Comparator: R4-HDAC (without DEX) High dose cytarabine alone	Drug: HD Cytarabine Consolidation chemotherapy course (s) : -High dose cytarabine: 3g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group
Experimental: R4-VEN-IDAC Intermediate dose cytarabine and venetoclax	Drug: ID cytarabine Consolidation chemotherapy course (s) : -Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group Drug: Venetoclax Consolidation chemotherapy course (s) : Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following: 100 mg/d on D1 to D8 (selection phase dose level 1) or 200 mg/d on D1 to D8 (selection phase dose level 2) or 400 mg/d on D1 to D8 (selection phase dose level 3) or 400 mg/d on D1 to D14 (selection phase dose level 4)
Active Comparator: R4-IDAC (without VEN) Intermediate dose cytarabine alone	Drug: ID cytarabine Consolidation chemotherapy course (s) : -Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group

Outcome Measures

Primary Outcome Measures

Overall survival [3 years]
For randomizations R1 (idarubicine vs daunorubicine) and R2 (HDAC vs IDAC)
Cumulative incidence (CI) of acute Graft versus Host Disease (GvHD) of grade II to IV [100 days]
For randomization R3 : GvHD prophylaxis study
Disease free survival [18 months]
For randomizations R4

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 61 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria (at diagnosis) :

Age ≥ 18 years and < 61 years
With a newly diagnosed de novo or secondary type AML (post myelodysplastic syndrome MDS or therapy-related AML)
No prior treatment for neither AML (with the exception of hydroxyurea), nor MDS (with the exception of EPO)
ECOG performance status ≤ 3
Absence of severe uncontrolled infection
No cardiac contraindications for the use of anthracyclines : decompensated or uncontrolled heart failure, recent myocardial infarction, current signs of cardiac impairment, uncontrolled arrhythmias, LVEF (left ventricular ejection fraction) < 50%
Total bilirubin ≤ 2 x upper limit of normal (UNL), ASAT(SGOT) and ALAT (SGPT) ≤ 2.5 X UNL, creatinine < 150 µmol/l, unless AML-related out of range values
Genetic mutation testing of the FLT3 (FLT3-ITD ou FLT3-TKD) gene, performed in local or central laboratory
Use of appropriate methods of contraception:

for patients treated with Midostaurin:
women of childbearing potential should use appropriate methods of contaception throughout treatment, and for 5 months post cessation of treatment
men will need to use condoms during intercourse throughout treatment, and for 5 months post cessation of treatment with Midostaurin

Patients who are covered by or beneficiaries of a social security system (Social Security or Universal Medical Coverage)
Patients who have read and understood the information sheet and signed the informed consent form

Exclusion criteria (at diagnosis) :

1.Patients with acute promyelocytic leukemia (APL), as confirmed either by t(15;17) or by the presence of PML-RARA fusion transcripts 2.Patients with core binding factor (CBF) AML, as confirmed either by t(8;21), t(16,16) or inv(16), or by fusion transcripts resulting from these cytogenetic abnormalities (RUNX1-RUNX1T1, CBFB-MYH11).

3.Patients with secondary AML arising from myeloproliferative disorders previously known according to the 2008 WHO classification 4.Patients with Ph1+ AML or previous Ph1+ disorder (chronic myelogenous leukemia) 5.Severe psychiatric or organic disorder, supposed to be independent from AML, that would contraindicate treatment, including allogeneic HSCT 6.No psychological, familial, social, or geographic reason that would compromise clinical follow up 7.History of uncontrolled cancer for the last 2 years, with the exception of basal cell carcinoma or carcinoma in situ of the cervix 8.Uncontrolled severe infection 9.Patients with positive serology for HIV-1 and -2, or HTLV -1 and -2, or active hepatitis virus B or C infection 10.Pregnant or lactating women 11.Legal incapacity (patients under tutorship, curatorship or judicial protection)

For randomization R4-VOS (post-induction/salvage) :

Inclusion criteria

Patients enrolled in the BIG-1 trial at diagnosis
Patient presenting with AML in first CR or CRp/CRi after induction or one cycle of salvage therapy (confirmed in the 15 days preceding R4-VOS)
Favorable or intermediate risk AML patients, as stratified with BIG-1 prognostic classification
Patients randomized to R2-IDAC arm (intermediate dose cytarabine)
ECOG performance status ≤ 2
Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
Local clinical laboratory values as follows:

o Serum creatinine ≤ 2.0 mg/dL

o Total bilirubin ≤ 1.5 X the upper limit of normal (ULN)

Aspartate aminotransferase (AST) ≤ 2.5 X ULN
Alanine aminotransferase (ALT) ≤ 2.5 X ULN

Signed written informed consent for vosaroxin study (R4-VOS)
Women of childbearing potential must have a negative pregnancy test within 8 days before randomization R4-VOS and commit to the use of effective contraception during the period of treatment and up to 36 days after vosaroxin has been stopped. Men must use effective contraception during the treatment period and up to 96 days after vosaroxin has been stopped.

Exclusion criteria

1.Patients classified in the unfavorable risk group according to the BIG-1 protocol classification 2.Complete remission is not attained (CR, CRp/CRi) after induction and/or salvage therapy 3.Positive pregnancy test 4.Severe uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever 5.Documented uncontrolled fungal infection (positive blood test and cultures) 6.History of myocardial infarction, unstable angina, cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months before randomization 7.Patient under hemodialysis (HD) or peritoneal dialysis (PD)

For randomization R4-DEX (post-induction/salvage) :

Inclusion criteria

Patients enrolled in the BIG-1 trial at diagnosis
Patient presenting with AML in first CR or CRp/CRi after induction or one cycle of salvage therapy (confirmed in the 15 days preceding R4-DEX)
Favorable or intermediate risk AML patients, as stratified with BIG-1 prognostic classification
ECOG performance status ≤ 2
Local clinical laboratory values as follows:

Serum creatinine ≤ 150 µmol/L
Total bilirubin ≤ 1.5 X the upper limit of normal (ULN)
Aspartate aminotransferase (AST) ≤ 2.5 X ULN
Alanine aminotransferase (ALT) ≤ 2.5 X ULN

Signed written informed consent for dexamethasone study (R4-DEX)

Exclusion criteria

1.Severe uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever 2.Documented uncontrolled fungal infection (positive blood test and cultures 3.History of myocardial infarction, unstable angina, cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months before randomization 4.Patient under hemodialysis (HD) or peritoneal dialysis (PD)

For randomization R4-VEN (post-induction/salvage) :

Inclusion criteria

Age 18 - 60 years at inclusion in BIG-1 protocol
diagnosis of AML according to WHO classification de novo or secondary to myelodysplastic syndrome (myelodysplastic syndrome must not have been treated except by ESA, Lenalidomide or non-chemotherapy) or therapy-related AML
Patients included in the BIG-1 protocol
Patients in first CR or CRp/CRi following 1 or 2 courses of induction chemotherapy according to BIG-1 protocol and who are planned to receive consolidation.
Patients stratified within the favorable and intermediate risk groups as defined by BIG-1 protocol
ECOG performance status ≤ 2
Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
Creatinine clearance ≥ 30 ml/min (calculated by the usual method of each institution), total bilirubin ≤ 1.5 times the ULN; ASAT and ALAT ≤ times the upper limit of normal (ULN)
Absence of uncontrolled infection
Women of childbearing potential must agree to use effective contraception without interruption throughout the study and for a further 3 months after the end of treatment
Written signed informed consent

Exclusion criteria

1.AML stratified in the unfavorable BIG-1 risk-group. 2.Diagnosis of Acute Promyelocytic Leukemia or CBF AML (ie. AML with t(8;21), t(16,16) or inv(16), or their molecular equivalents RUNX1-RUNX1T1 and CBFB-MYH11) 3.AML secondary to prior myeloproliferative disorder according to WHO classification (2008) and Philadelphia chromosome-positive AML (Ph1+) 4.Absence of CR/CRp/CRi after a maximum of two chemotherapy cycles 5.Severe medical or mental condition precluding the administration of protocol treatments 6.Prior history of cancer unless controlled for at least 2 years and except for basocellular cutaneous cancers and in situ cervix cancers 7.Positive pregnancy test 8.Breast feeding 9.Uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever 10.Documented uncontrolled fungal infection (positive blood test and cultures) 11.Prior venetoclax exposure 12.Known HBV with detectable viral load 13.Known HIV positive patients 14.Known hypersensitivity to any of the study medication 15.History of myocardial infarction, unstable angina, cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months before randomization 16.Patient under hemodialysis (HD) or peritoneal dialysis (PD) 17.Concomitant treatment with cytochrome CYP3A4 inhibitor which cannot be stopped during venetoclax administration ONLY FOR PHASE 1 18.During the phase 2, for patients randomized in the IDAC + Venetoclax arm, if concomitant treatment with cytochrome CYP3A4 inhibitor cannot be stopped, a dose reduction of 70% of venetoclax must be apply

For randomization R3 (before AlloHSCT):

Inclusion criteria

Patients enrolled in the BIG-1 trial at diagnosis
Patient presenting with AML in first CR or CRp/CRi treated in the BIG-1 trial and classified in the intermediate risk group, namely:

either initially favorable but poor molecular responders for NPM1 MRD: NPM1 mutation, without FLT3-ITD mutation or with an FLT3-ITD ratio < 0.50 and MRD2 positive blood (decrease of less than 4 log from baseline at diagnosis)).
Or initially favorable but requiring two cycles of chemotherapy (a salvage therapy) to obtain the first CR/CRp/CRi
Or other immediate intermediaries

No metastatic or progressive cancer, with the exception of basal cell skin carcinoma and cervical carcinoma in situ
Patients with general condition preserved (ECOG ≤ 3) and with no uncontrolled severe infection
Women of childbearing age must make use of effective contraception
Patients who are covered by or beneficiaries of a social security system (Social Security or Universal Medical Coverage).
Patients who have read and understood the information sheet and signed the informed consent form

Exclusion criteria

Complete remission is not obtained (CR, CRp/CRi) after induction and/or salvage therapy
Patient presenting with AML in first CR or CRp/CRi treated in the BIG-1 trial and classified either in the favorable risk group or the unfavorable risk group
Patients with a severe organ or psychiatric pathology, presumed to be independent of AML and contraindicating the allograft
Patients who, for family, social or geographic reasons, do not wish to be regularly monitored via consultation
Uncontrolled severe infection at the time of inclusion
Serology positive for HIV 1 or 2 or HTLV 1 or 2, or active HBV or HCV viral infection
Pregnant women (beta-HCG positive) or currently breastfeeding
Adult patient who is incapacitated, under wardship, legal guardianship, or under the protection of the courts
Patients under State Medical Assistance (AME)

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	CH Amiens Hôpital Sud	Amiens	France
2	CHU Angers	Angers	France	49100
3	CH Victor Dupouy	Argenteuil	France
4	Centre Hospitalier de la Côte Basque	Bayonne	France
5	Hôpital Jean Minjoz	Besancon	France
6	CH Beziers	Beziers	France
7	Hôpital Avicenne	Bobigny	France
8	CH Bordeaux	Bordeaux	France
9	Hôpital du Dr Duchenne	Boulogne sur Mer	France
10	Hôpital Morvan	Brest	France
11	CH Caen	Caen	France
12	Clinique du parc	Castelnau Le lez	France	34170
13	Centre Hospitalier René Dubos	Cergy Pontoise	France
14	HIA Percy	Clamart	France
15	CHU Estaing	Clermont-Ferrand	France
16	Centre Hospitalier Sud Francilien	Corbeil Essonnes	France
17	Hôpital Henri Mondor	Créteil	France
18	CHU de Dijon	Dijon	France
19	CH Dunkerque	Dunkerque	France
20	Hôpital Michallon	Grenoble	France
21	CH Versailles	Le Chesnay	France
22	CH Lens	Lens	France
23	CHRU de Lille, Hôpital Huriez	Lille	France
24	Hôpital St Vincent de Paul	Lille	France
25	CHU de Limoges	Limoges	France
26	Centre Leon Berard (CLB)	Lyon	France
27	CH Lyon Sud	Lyon	France
28	Institut Paoli Calmettes	Marseille	France
29	CH Meaux	Meaux	France
30	CHR Metz Thionville_Hôpital de Mercy	Metz	France
31	Hôpital Saint Eloi	Montpellier	France
32	CH Mulhouse	Mulhouse	France
33	CH Hôtel Dieu	Nantes	France
34	Centre Antoine Lacassagne	Nice	France
35	CHU Nice	Nice	France
36	CHRU de Nîmes	Nîmes	France
37	Hôpital Cochin	Paris	France
38	Hôpital La Pitié Salpêtrière	Paris	France
39	Hôpital Necker Enfants Malades	Paris	France
40	Hôpital Saint Antoine	Paris	France
41	Hôpital St Louis	Paris	France
42	Centre Hospitalier Saint Jean	Perpignan	France
43	CHU de Poitiers	Poitiers	France
44	Hôpital Robert Debré	Reims	France
45	CH Pontchaillou	Rennes	France
46	Hopital Victor Provo	Roubaix	France
47	Centre Henri Becquerel	Rouen	France
48	Hôpital René Huguenin	St Cloud	France
49	Institut de Cancérologie Lucien Neuwirth	St Priest en Jarez	France
50	Hôpital Hautepierre	Strasbourg	France
51	IUCT Toulouse	Toulouse	France
52	CHU Bretonneau	Tours	France
53	CH Valenciennes	Valenciennes	France
54	Hôpitaux de Brabois_CHU Nancy	Vandoeuvre-les-Nancy	France
55	Institut de Cancérologie Gustave Roussy	Villejuif	France